We recently demonstrated the feasibility of targeting CREB for AML treatment using XX-650-23, a small molecule inhibitor of CREB function, which is based on naphthol AS-E phosphate that was first identified as an inhibitor of CREB interaction with its coactivator, CREB Binding Protein (CBP) [17]. This evidence concerns the gene CREB1 and acute myeloid leukemia.